New therapy offers hope as cancer injection shows strong results

The study involved 102 patients suffering from incurable head and neck cancers.

A recent clinical trial has revealed that a new cancer treatment injection may deliver promising results even for patients with advanced disease where treatment options are nearly exhausted.

The drug, named Immunetimab, is a triple-action injection that is already available for certain patients. It works by blocking proteins and enzymes that help tumors evade the immune system, while also stimulating white blood cells to more effectively attack cancer cells.

The study involved 102 patients suffering from incurable head and neck cancers. Following treatment, tumors shrank in 42% of the participants.

Most notably, in 15 cases, tumors disappeared completely—even among patients who had stopped responding to chemotherapy and immunotherapy.

Head and neck cancers include tumors of the mouth, throat, and tongue. In the United Kingdom, it is the ninth most common type of cancer, affecting around 13,000 people annually.

Study lead researcher Professor Kevin Harrington said the results were “highly unusual” in patients whose disease had become resistant to both chemotherapy and immunotherapy, adding that treatment options for such cases are usually extremely limited, making the observed benefits particularly encouraging.